The study of the therapeutic action of the cell-associated antigens of candida albicans and candida tropicalis fungi


  • M. V. Rybalkin National University of Pharmacy, Ukraine



candidiasis, antigen, vaccine, therapy


Fungi of Candida genus are the most widespread causative agent of fungal infections. Candida causes a wide range of infections: from insignificant diseases of the skin and mucous membranes to invasion processes that can practically destroys all organs. Development of a vaccine against candidiasis is the topical issue of modern pharmacy and medicine. Suspensions of cells of Candida albicans and Candida tropicalis fungi were subjected to the action of ultrasound, then filtered through a “Vladipore” membrane MFA-MA No.3 providing separation of the biological material with the size of 10 kDa and its concentration. Then prefiltration and sterilizing filtration were carried out. The resulting purified antigens of Candida albicans fungi cells with the protein concentration of 3 mg/ml and Candida tropicalis with the protein concentration of 5 mg/ml were mixed in the ratio of 1:1 using a mixer with the rotation speed of 100 rpm for 10 min. In the experiment two-month white mice with the body weight of 18-22 g were used; there were 6 animals in the control and test groups. The animals were infected intraperitoneally with the suspension of Candida albicans in the amount of 20 mln of cells and Candida tropicalis in the amount of 60 mln of cells in the volume of 1 ml. In 5 days the cell-associated antigens of Candida fungi in the volume of 0.2 ml were injected intramuscularly to mice in the upper part of the rear right paw. In 14 days the procedure was repeated. The animals of the control group were injected with the sterile 0.9% isotonic saline solution. After that in 14 days the animals were examined and the results were determined. According to the research results it has been found that the cell-associated antigens of Candida albicans and Candida tropicalis provide the therapeutic effect in 100% of animals when injected intramuscularly in the volume of 0.2 ml.


Миленина О.Е., Кравцов Э.Г., Кузьменко Л.Г. и др. // Проблемы мед. микол. – 2006. – Т. 8, №3. – С. 14-16.

Пат. 2352355 РФ, МПК7 A 61 K 39/00, A 61 P 31/00. – 2007139596/13. – Заявл.: 25.10.2007. Опубл.: 25.10.2007.

Резниченко Н.А. // Здоровье женщины. – 2006. – №3 (27). – С. 53-55.

Aditi Grover, Bhandari B.S., Rai Nishant, Pramesh C. Lakhera // Biotechnol. International. – 2010. – Vol. 3, №1. – P. 4-17.

Carvalho A. // Front. Microbiol. – 2012. – Vol. 3. – P. 1-9.

Cassone A. // Nature Reviews Microbiol. – 2013. – Vol. 11. – P. 884-891.

Diekema D., Arbefeville S., Boyken L. et al. // Diagn. Microbiol. Infect. Dis. – 2012. – Vol. 73. – P. 45-48.

Han Y., Rhew K.Y. // Arch. Pharm. Res. – 2012. – Vol. 35. – P. 2021-2027.

Nabel G.J. // N. Eng. J. Med. – 2013. – Vol. 6, №368. – Р. 551-60.

Skibinski A.G., David and Barbara C. Baudner, Singh Manmohan, O’Hagan T. Derek // Glob. Infect. Dis. – 2011. – Vol. 3, №1. – P. 63-72.






Experimental and Clinical Pharmacology